Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.
(Alcoholic fatty liver disease)
21,965 results
  • Association between maternal obesity, essential fatty acids and biomarkers of fetal liver function. [Journal Article]
    Prostaglandins Leukot Essent Fatty Acids. 2023 Jan 16; 190:102541.Ortiz M, Sánchez F, … Maliqueo M
  • Maternal obesity and the imbalance in linoleic acid (C18:2 n-6, LA) and alpha-linolenic acid (C18:3 n-3, ALA) levels are related with hepatic disturbances in the offspring. However, whether these alterations are present during fetal life is not well understood. Obese and normal weight pregnant women were recruited to determine fatty acids (FAs) consumption, FAs profile (in maternal erythrocytes, …
  • [Clinical Features and Treatment for Cholangiolocellular Carcinoma(CoCC)-Report of Three Cases]. [Journal Article]
    Gan To Kagaku Ryoho. 2022 Dec; 49(13):1968-1970.Tamai M, Harada K, … Otsuji E
  • We report 3 cases of cholangiolocellular carcinoma(CoCC)experienced from April 2017 to March 2021 in our hospital. The average age of the cases is 74.3 years old, 2 males and 1 female respectively. Hepatectomy was performed in 2 cases, and transcatheter arterial embolization(TAE)and radiofrequency ablation(RFA)therapy was performed in 1 case because of old age and his wishes as the background liv…
  • Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD). [Review]
    Front Endocrinol (Lausanne). 2022; 13:1087260.Rong L, Zou J, … Guo J
  • Non-alcoholic fatty liver disease (NAFLD) is a series of diseases, involving excessive lipid deposition in the liver and is often accompanied by obesity, diabetes, dyslipidemia, abnormal blood pressure, and other metabolic disorders. In order to more accurately reflect its pathogenesis, an international consensus renamed NAFLD in 2020 as metabolic (dysfunction) associated with fatty liver disease…
  • Bariatric Surgery and Metabolic Dysfunction-Associated Fatty Liver Disease: a 2022 Update. [Review]
    Praxis (Bern 1994). 2023 Feb; 112(2):97-102.Lazaridis II, Delko T
  • Non-alcoholic fatty liver disease (NAFLD) has been recently termed metabolic dysfunction-associated fatty liver disease (MAFLD) to address the strong association with the metabolic syndrome. The prevalence of MAFLD is significantly increased in obese individuals and treatment of obesity is currently the cornerstone of management of MAFLD. Bariatric and metabolic surgery nowadays emerges as a key …
  • Bavachin protects against diet-induced hepatic steatosis and obesity in mice. [Journal Article]
    Acta Pharmacol Sin. 2023 Jan 31 [Online ahead of print]Wei X, Lin L, … Zhang HB
  • Non-alcoholic fatty liver disease (NAFLD) is a major health concern worldwide, and the incidence of metabolic disorders associated with NAFLD is rapidly increasing because of the obesity epidemic. There are currently no approved drugs that prevent or treat NAFLD. Recent evidence shows that bavachin, a flavonoid isolated from the seeds and fruits of Psoralea corylifolia L., increases the transcrip…
  • Nutrition literacy is not sufficient to induce needed dietary changes in NAFLD. [Journal Article]
    Am J Gastroenterol. 2023 Jan 13 [Online ahead of print]Carroll AM, Rotman Y
  • CONCLUSIONS: Subjects with NAFLD have poor diet quality despite receiving medical recommendations to lose weight and having nutrition literacy and perception that are comparable to subjects without NAFLD. Educational approaches may not be sufficient to promote weight loss and improve diet quality in NAFLD.
  • PNPLA3 I148M and response to treatment for hepatic steatosis. A systematic review. [Journal Article]
    Liver Int. 2023 Jan 31 [Online ahead of print]Boeckmans J, Gatzios A, … Vanhaecke T
  • CONCLUSIONS: NAFLD patients homozygous for the PNPLA3 148M allele might not benefit from omega-3 carboxylic acids to reduce hepatic steatosis, in contrast to patients with wildtype PNPLA3. Instead, patients with two PNPLA3 148M alleles should be especially encouraged to adopt lifestyle changes. Genotyping for PNPLA3 I148M should be encouraged in therapeutic studies for NAFLD. PROSPERO registration number: CRD42022375028.
New Search Next